Search Result

Results for "

viral replication inhibition

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) Apoptosis (1) CMV (2) Dengue Virus (1) DNA/RNA Synthesis (7) Drug Derivative (1) Drug Metabolite (4) Endogenous Metabolite (1) Glycosyltransferase (1) HCV (2) HIV (6) HIV Protease (5) HSV (1) Influenza Virus (1) Nucleoside Antimetabolite/Analog (4) Orthopoxvirus (1) RAR/RXR (1) SARS-CoV (3)
By Research Areas:	Cancer (3) Infection (15)
Click Chemistry:	Azide (1)
Oligonucleotides:	Nucleotide Analogs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-120072

PF-3450074 5 Publications Verification PF-74	HIV	Infection
PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC₅₀=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.

HY-137697D

ddCTP trisodium solution (100 mM)	HIV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Drug Metabolite HIV Protease	Infection
ddCTP trilithium solution (100 mM) is a chain-terminating dideoxynucleotide. ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-131944

S-Acetylglutathione	Apoptosis HSV	Infection Cancer
S-Acetylglutathione is a derivative of Glutathione (HY-D0187). S-Acetylglutathione is stable in blood, and can be converted to glutathione by intracellular thioesterases. S-Acetylglutathione restores the intracellular glutathione content in glutathione synthetase deficient fibroblasts. S-Acetylglutathione exhibits antiviral efficacy in HSV-1 infected model through inhibition of viral replication. S-Acetylglutathione induces apoptosis in cancer cells MOLT4 and UKF-NB-3 .

HY-131605B

Ganciclovir triphosphate disodium GCV-TP disodium	CMV DNA/RNA Synthesis	Infection Cancer
Ganciclovir triphosphate (GCV-TP) disodium is a synthetic 2'-deoxyguanosine analog with activity in inhibiting human cytomegalovirus (CMV) replication. Ganciclovir triphosphate disodium is effective against CMV infection by binding to viral DNA polymerase and interfering with viral DNA synthesis. Ganciclovir triphosphate disodium has an IC₅₀ of 0.01 μM against CMV strains from humans, monkeys, mice, and guinea pigs. Ganciclovir triphosphate disodium has also been used in gene-directed enzyme prodrug inhibition for cancer inhibition .

HY-137697

ddCTP	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis HIV Protease HIV Drug Metabolite	Infection
ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-131605

Ganciclovir triphosphate GCV-TP	Endogenous Metabolite CMV DNA/RNA Synthesis	Infection Cancer
Ganciclovir triphosphate (GCV-TP) is a synthetic 2'-deoxyguanosine analog with activity in inhibiting human cytomegalovirus (CMV) replication. Ganciclovir triphosphate is effective against CMV infection by binding to viral DNA polymerase and interfering with viral DNA synthesis. Ganciclovir triphosphate has an IC₅₀ of 0.01 μM against CMV strains from humans, monkeys, mice, and guinea pigs. Ganciclovir triphosphate has also been used in gene-directed enzyme prodrug inhibition for cancer inhibition .

HY-137697B

ddCTP trilithium	HIV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Drug Metabolite HIV Protease	Infection
ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-128660

RYL-634	HCV Dengue Virus Influenza Virus	Infection
RYL-634 is a potent broad-spectrum antiviral agent. RYL-634 exerts its antiviral effect by inhibiting the activity of human dihydroorotate dehydrogenase (HsDHODH) and blocking the supply of pyrimidines required for viral replication. RYL-634 shows significant inhibition against many viruses, with the EC₅₀ values against DENV, ZIKV, EV71, HCV and HIV are 7 nM, 20 nM, 4 nM, 5 nM and 13 nM respectively. RYL-634 can be used for the study of various virus infection-related diseases .

HY-162154

SARS-CoV-2-IN-75	SARS-CoV	Infection
SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC₆₈ (half-log reduction in viral titer) of 3 μM .

HY-175697

Glycosyltransferase-IN-2	Glycosyltransferase SARS-CoV Angiotensin-converting Enzyme (ACE) DNA/RNA Synthesis	Infection
Glycosyltransferase-IN-2 (Compound 20) is a Glycosyltransferase inhibitor. Glycosyltransferase-IN-2 has a broad-spectrum anticoronavirus activity with IC₅₀s of 11.3, 5.5 and ~16.2 μM for MHV, HCoV-NL63 and SARS-CoV-2, respectively. Glycosyltransferase-IN-2 interferes with the coronavirus infectivity, alters viral protein glycosylation with inhibition of interaction with the ACE2 receptor or SC-VLP secretion, and inhibits RNA replication. Glycosyltransferase-IN-2 can be used for coronavirus infections research .

HY-P11546

Antiviral agent 76	HCV	Infection
Antiviral agent 76 is an antiviral peptide containing azide groups, which has anti-hepatitis C virus (HCV) activity .

HY-137697A

ddCTP tetrasodium	Drug Metabolite HIV Nucleoside Antimetabolite/Analog HIV Protease DNA/RNA Synthesis	Infection
ddCTP tetrasodium is a type of chain-terminating deoxynucleotide. ddCTP tetrasodium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP tetrasodium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP tetrasodium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-183592

Anti-virus agent 2	Orthopoxvirus Drug Derivative	Infection
Anti-virus agent 2 is an orally active and selective anti-orthopoxvirus (poxvirus) agent, with EC₅₀ values of 6.1 μM and 47.1 μM against VTT-Fluc and MPXV clade IIb, respectively. Anti-virus agent 2 covalently binds to viral A17L protein and mRNA methyltransferase, blocks viral membrane fusion and intracellular biosynthesis, and acts on multiple stages of the viral replication cycle. Anti-virus agent 2 achieves viral inhibition in nude mouse models. Anti-virus agent 2 can be used for the research of orthopoxvirus infections such as monkeypox and smallpox .

HY-126120

BILA 1906 BS	HIV HIV Protease	Infection
BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .

HY-W816575

MDI-403	RAR/RXR SARS-CoV	Infection
MDI-403 is a retinoic acid receptor (RAR) agonist with an EC₅₀ value of less than 1 μM. MDI-403 exhibits significant antiviral activity against SARS-CoV-2, and can dose-dependently inhibit the expression of viral nucleoprotein (NP) and reduce the proportion of infected cells. MDI-403 mainly acts during the virus invasion stage. MDI-403 can be used in research on anti-SARS-CoV-2 .

Cat. No.	Product Name

HY-L044

Nucleotide Compound Library	572 compounds
Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications. MCE offers a unique collection of 572 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

Nucleotide Compound Library

572 compounds

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 572 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

Cat. No.	Product Name	Type

HY-137697

ddCTP	Biochemical Assay Reagents
ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

ddCTP

Biochemical Assay Reagents

ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

Cat. No.	Product Name	Target	Research Area

HY-P11546

Antiviral agent 76	HCV	Infection
Antiviral agent 76 is an antiviral peptide containing azide groups, which has anti-hepatitis C virus (HCV) activity .

Cat. No.	Product Name		Classification

HY-P11546

Antiviral agent 76		Azide
Antiviral agent 76 is an antiviral peptide containing azide groups, which has anti-hepatitis C virus (HCV) activity .

Cat. No.	Product Name		Classification

HY-137697D

ddCTP trisodium solution (100 mM)		Nucleotide Analogs
ddCTP trilithium solution (100 mM) is a chain-terminating dideoxynucleotide. ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

HY-137697

ddCTP		Nucleotide Analogs
ddCTP is a type of chain-terminating deoxynucleotide. ddCTP can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.